Impact of the Use of Nandrolone on the Treatment of Malnutrition Induced by Cancer

• Status: Completed
• Trial end date: 2017-10-31
• Target enrollment: 0
• Participant gender: All

Summary

Compare the use of nandrolone associated with corticosteroid for the treatment of cancer-induced malnutrition to treatment with corticosteroids alone in patients with tumors in the high gastro-intestinal tract, liver, pancreas and bile ducts in palliative treatment.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital Erasto Gaertner
• Treatments: BB 1101; Decanoic acid; Dexamethasone; Dexamethasone acetate; Nandrolone; Nandrolone Decanoate; Nandrolone phenpropionate

Criteria

Inclusion Criteria:

• Cancer patients above 18 years old.

• Patients with tumors in the high gastro-intestinal, hepatobiliary and pancreatic tracts in palliation.

• Patients able to undergo BIA.

• Malnourished patients as per the subjective global assessment produced by the patient (ASG-PPP) and whose score is greater than nine.

• Patients who agree to participate in the study.

Exclusion Criteria:

• Patients with malignant tumors of other metachronous or synchronous location except nonmelanoma skin tumor

• Patients with chronic renal failure.

• Patients on diuretics, recent or chronic.

• Patients on appetite stimulants and anabolic agents.

• Patients using pacemakers, which can interfere with the results of BIA